e0484 The safety study of tirofiban in patients with STEMI during emergency PCI

Objective To assess the safety of GP IIb/IIIa antagonists tirofiban in patients with ST elevation myocardial infarction (STEMI) during emergency Percutaneous Coronary Intervention (PCI). Method 120 patients with STEMI during emergency PCI, divided into two groups, tirofiban+PCI group (n=60) and primary PCI group (n=60). The two groups are compared on their major adverse cardiovascular events (MACE) rates which consisted of death, new onset myocardial infarction, persistent myocardial ischeamic state, Cardiac function (1eft ventricular ejection fraction) after operation, compression haemostasia time and adverse drug effect while in hospital. Result Major adverse cardiovascular events (MACE) rates in tirofiban+PCI group was higher than that of primary PCI group (10% vs 6.7%); Postoperative heart function was better in tirofiban+PCI group than that in primary PCI group (56.97±8.41 vs 54.15±7.11): There was no difference in severe haemorrhage between the two groups.The bleeding event rates were of higher tendency in tirofiban+PCI group. (8.3% vs 3.3%). APTT and compression haemostasia time of tirofiban+PCI group were significant when prolonged (53.97±10.58 vs 32.51±6.31) p Conclusion GPII b/III a antagonists tirofiban+PCI is a possible safe and effective reperfusion method with STEMI during emergency PCI.